Trial Profile
A Pharmacokinetic Study of AC480 Administered Twice Daily in Surgically Resectable Malignant Glioma Patients Not on Enzyme-Inducing Anticonvulsants.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs BMS 599626 (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
- Focus Pharmacokinetics
- 28 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials/gov record.
- 18 Sep 2012 Planned end date changed from 1 Jun 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 21 Feb 2012 Planned end date changed from 1 Nov 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.